DUSA Pharmaceuticals (DUSA) +37.7% premarket after agreeing to be acquired by India's Sun Pharma for $8/share, giving the deal a total cash value of ~$230M. The price represents a 38% premium to DUSA's closing price yesterday. Dermatology company DUSA develops and markets the Levulan photodynamic therapy platform for the face and scalp
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.